ARCH Venture Management, LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), ARCH Venture Management, LLC reported 9 stock positions worth $260.6 million. Its top holding was Beam Therapeutics (BEAM) at 45.5% of the portfolio, followed by Rapport Therapeutics (RAPP, 29.3%) and Erasca (ERAS, 11.6%). Compared with Q2 2024, it reduced 1. The biggest sale was Beam Therapeutics (BEAM, shares −11%).
- Most Recent 13F
- Q2 2026
- Location
- CHICAGO, IL
- CIK
- 0001274403
- Portfolio Value
- $260.6M (Q3 2024)
- SEC Filing
- 0001012975-24-000476 ↗ filed Nov 14, 2024
Holdings Value
Holdings 9 stocks · $260.6M
| BEAM Beam Therapeutics Inc. | 45.46% | 4,834,653 | $118.4M | Reduce -11.2% |
| RAPP Rapport Therapeutics Inc. | 29.31% | 3,728,738 | $76.4M | No change |
| ERAS Erasca Inc. | 11.58% | 11,055,554 | $30.2M | No change |
| QTTB Q32 Bio Inc. | 5.49% | 320,482 | $14.3M | No change |
| VERV Verve Therapeutics Inc. | 3.73% | 2,008,809 | $9.7M | No change |
| GOSS Gossamer Bio Inc. | 3.05% | 8,055,916 | $7.9M | No change |
| OMIC Singular Genomics Systems Inc. | 0.76% | 126,630 | $2.0M | No change |
| UNBX Unity Biotechnology Inc. | 0.57% | 1,004,817 | $1.5M | No change |
| CERO THERAPEUTICS HLDGS INC | 0.05% | 1,444,296 | $135K | No change |
Portfolio Sells Q2 2024 → Q3 2024
| BEAM Beam Therapeutics Inc. | Reduce -11.2% | 45.46% | −2.48 |
Portfolio Buys Q2 2024 → Q3 2024
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 12 | $1.1B | PBLS, BEAM, RAPP, SPTX, ERAS |
| Q1 2026 | 10 | $677.1M | MAZE, RAPP, VIR, ERAS, BEAM |
| Q4 2025 | 9 | $651.7M | MAZE, BEAM, RAPP, LYEL, VIR |
| Q3 2025 | 9 | $492.4M | RAPP, BEAM, MAZE, VIR, LYEL |
| Q2 2025 | 11 | $299.1M | BEAM, VIR, MAZE, RAPP, VERV |
| Q1 2025 | 9 | $206.2M | BEAM, MAZE, RAPP, ERAS, VERV |
| Q4 2024 | 9 | $230.2M | BEAM, RAPP, ERAS, VERV, GOSS |
| Q3 2024 | 9 | $260.6M | BEAM, RAPP, ERAS, QTTB, VERV |
| Q2 2024 | 9 | $266.0M | BEAM, RAPP, ERAS, VERV, GOSS |
| Q1 2024 | 8 | $80.3M | VERV, ERAS, GOSS, DNLI, QTTB |